SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Bristol Myers Squibb Co – ‘8-K’ for 3/1/21

On:  Thursday, 3/4/21, at 4:30pm ET   ·   For:  3/1/21   ·   Accession #:  1140361-21-7317   ·   File #:  1-01136

Previous ‘8-K’:  ‘8-K’ on 2/23/21 for 2/19/21   ·   Latest ‘8-K’:  This Filing

Magnifying glass tilted right emoji
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/04/21  Bristol Myers Squibb Co           8-K:5,9     3/01/21   11:212K                                   Broadridge Fin’l So… Inc

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     31K 
 7: R1          Document and Entity Information                     HTML     57K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 6: XML         XBRL Instance -- brhc10021324_8k_htm                 XML     25K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 3: EX-101.DEF  XBRL Definitions -- bmy-20210301_def                 XML     52K 
 4: EX-101.LAB  XBRL Labels -- bmy-20210301_lab                      XML     79K 
 5: EX-101.PRE  XBRL Presentations -- bmy-20210301_pre               XML     57K 
 2: EX-101.SCH  XBRL Schema -- bmy-20210301                          XSD     17K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               16±    22K 
11: ZIP         XBRL Zipped Folder -- 0001140361-21-007317-xbrl      Zip     14K 

‘8-K’   —   Current Report

This is an HTML Document rendered as filed.  [ Alternative Formats ]

 iX:   C: 
 i false i 000001427200000142722021-03-012021-03-010000014272bmy:CelgeneContingentValueRightsMember2021-03-012021-03-010000014272bmy:One750NotesDue2035Member2021-03-012021-03-010000014272bmy:One000NotesDue2025Member2021-03-012021-03-010000014272us-gaap:CommonStockMember2021-03-012021-03-01

Washington, D.C. 20549

FORM  i 8-K

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  i March 1, 2021

(Exact Name of Registrant as Specified in its Charter)

 i Delaware
(State or Other Jurisdiction of Incorporation)
 i 001-01136
(Commission File Number)
 i 22-0790350
(IRS Employer Identification Number)
 i 430 East 29th Street,  i 14th Floor
 i New York,  i NY,  i 10016
(Address of Principal Executive Office)

Registrant’s telephone number, including area code: ( i 212)  i 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
 i Common Stock, $0.10 Par Value
 i BMY
 i New York Stock Exchange
 i 1.000% Notes due 2025
 i BMY25
 i New York Stock Exchange
 i 1.750% Notes due 2035
 i BMY35
 i New York Stock Exchange
 i Celgene Contingent Value Rights
 i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  i 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)          On March 1, 2021, Mr. Dinesh Paliwal notified Bristol-Myers Squibb Company that he will not stand for re-election to the Board of Directors at the 2021 Annual Meeting of Shareholders.  The Board also set the number of directors at ten effective as of the 2021 Annual Meeting of Shareholders, which is expected to be held on May 4, 2021.

Item 9.01.
Financial Statements and Exhibits.
 (d) Exhibits
The following exhibit is included as part of this Current Report on Form 8-K:
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).


The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Corporate Secretary

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:3/4/21
For Period end:3/1/214
 List all Filings 
Filing Submission 0001140361-21-007317   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2021 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., Apr. 18, 10:23:31.0am ET